Advancement in Heart Failure

The prevalence of heart failure (HF) continues to increase over time1 and affects >60 million people each year2.

Therefore, being aware of the latest data in the HF space and different treatment options is important in order to be able to apply findings to clinical practice when making treatment decisions for patients with type 2 diabetes mellitus (T2DM) and cardiovascular disease, especially HF.

Close X
Other videos you might like

This section is supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company Alliance

Recent Videos

Video Series

Advances In HF: A Year In Discovery – SGLT2i Trials And Implications For…
Ileana L Piña, Shelley Zieroth

Video Series

Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors

Video

Past, Present and Future: SGLT2 Inhibitors for Cardiovascular Outcomes -…

Video

Past, Present and Future: SGLT2 Inhibitors for Cardiovascular Outcomes -…

Video

ESC 2019: DAPA-HF: The Dapaglifozin and Prevention of Adverse Outcomes in…
Frank Ruschitzka

Video

SGLT2 beyond diabetes
Lars H Lund
Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program

Rådholm K, Figtree G, Perkovic V, et al. Circulation 2018;138:458–68.

Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction

Zhang N, Feng B, Ma X, et al. Cardiovasc Diabetol 2019;18:107.

Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus

Figtree GA, Rådholm K, Barrett TD, et al. Circulation 2019;139:2591–3.

Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes

Petrie MC, Verma S, Docherty KF, et al. JAMA 2020;323:1353–68.

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato ET, Silverman MG, Mosenzon O, et al. Circulation 2019;139:2528–36.

Vericiguat in patients with heart failure and reduced ejection fraction

Armstrong PW, Pieske B, Anstrom KJ, et al. N Engl J Med 2020;382:1883–93.

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

Docherty KF, Jhund PS, Inzucchi SE, et al. Eur Heart J 2020;41:2379–92.

Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction

Solomon SD, McMurray JJV, Anand IS, et al. N Engl J Med 2019;381:1609–20.

Effect of treatment with dapagliflozin according to baseline systolic blood pressure in patients with HFrEF: an analysis of the DAPA-HF trial

McMurray J, Boehm M, Serenelli M, et al. J Am Coll Cardiol 2020;75(Supplement 1):849.

PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: results of the PRIME-HF trial

Mentz RJ, DeVore AD, Tasissa G, et al. Am Heart J 2020;223:98–105.

Effect of treatment with dapagliflozin is consistent across the range of body mass index in patients with HFrEF: an analysis of the DAPA-HF trial

Jhund P, Adamson C, Inzucchi SE, et al. J Am Coll Cardiol 2020;75(Supplement 1):673.

Risk score–guided multidisciplinary team-based Care for Heart Failure Inpatients is associated with lower 30-day readmission and lower 30-day mortality

Horne BD, Roberts CA, Rasmusson KD, et al. Am Heart J 2020;219:78–88.

Dapagliflozin improves outcomes irrespective of NT-proBNP concentration in patients with HFrEF: an analysis of the DAPA-HF trial

Køber L, Docherty K, Inzucchi SE, et al. Journal of the American College of Cardiology 2020;75(Supplement 1):675.

Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial

Slee A, Saksena S. Am Heart J 2020;220:1–11.

Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to age: insights from DAPA-HF

Martinez FA, Serenelli M, Nicolau JC, et al. Circulation 2020;141:100–11.

Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial

Nassif ME, Windsor SL, Tang F, et al. Circulation 2019;140:1463–76.

Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus

Striepe K, Jumar A, Ott C, et al. Circulation 2017;136:1167–9.

Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors

Verma S, Rawat S, Ho KL, et al. JACC Basic Transl Sci 2018;3:575–87.

The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine MJ, Mahaffey KW, Neal B, et al. Am J Nephrol 2017;46:462–72.

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

McMurray JJV, DeMets DL, Inzucchi SE, et al. Eur J Heart Fail 2019;21:665–75.

SUN-149 cardiologist vs. endocrinologist encounters in patients with T2D and CVD: potential implications for glucose-lowering therapy use and education

Gunawan F, Partridge C, Kosiborod M, Inzucchi S. Journal of the Endocrine Society 2019;3(Supplement_1):SUN-149.

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study

Pasternak B, Ueda P, Eliasson B, et al. BMJ 2019;366:l4772.

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial

Fitchett D, Zinman B, Wanner C, et al. Eur Heart J 2016;37:1526–34.

Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus

Berg DD, Wiviott SD, Scirica BM, et al. Circulation 2019;140:1569–77.

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors

Sama IE, Ravera A, Santema BT, et al. Eur Heart J 2020;41:1810–7.

Angiotensin-neprilysin inhibition versus enalapril in heart failure

McMurray JJ, Packer M, Desai AS, et al. N Engl J Med 2014;371:993–1004.

Dapagliflozin in patients with heart failure and reduced ejection fraction

McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med 2019;381:1995–2008.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

Zinman B, Wanner C, Lachin JM, et al. N Engl J Med 2015;373:2117–28.

Canagliflozin and cardiovascular and renal events in type 2 diabetes

Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med 2017;377:644–57.

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure

Abraham WT, Ponikowski P, Brueckmann M, et al. Eur J Heart Fail 2019;21:932–42.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic V, Jardin, MJ, Neal B, et al. N Engl J Med 2019;380:2295–306.

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

Jensen J,Omar M, Kistorp C, et al. Trials 2019;20:374.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott SD, Raz I, Mosenzon O, et al. N Engl J Med 2019; 380:347–57.

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Yancy CW, Jessup M, Bozkurt B, et al. Circulation 2013;128:e240–e327.

2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of Amer

Yancy CW, Jessup M, Bozkurt B, et al. Circulation 2017;136:e137–e161.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of

Ponikowski P, Voors AA, Anker SD, et al. Eur Heart J 2016;37:2129–200.

2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on expert consensus deci

Das SR, Everett BM, Birtcher KK, et al. J Am Coll Cardiol 2018;72:3200–23.

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Anker SD, Butler J, Khan MS, et al. Eur Heart J 2020;41:2109–17.

American association for thoracic surgery/international society for heart and lung transplantation guidelines on selected topics in mechanical circulatory support

Kirklin JK, Pagani FD, Goldstein DJ, et al. J Thorac Cardiovasc Surg 2020;159:865–96.

Consensus document and recommendations on palliative care in heart failure of the Heart Failure and Geriatric Cardiology Working Groups of the Spanish Society of Cardiology

García Pinilla JM, Díez-Villanueva P, Bover Freire R, et al. Rev Esp Cardiol (Engl Ed) 2020;73:69–77.

Series: implications of the recent CVOTs in type 2 diabetes: impact on guidelines: the endocrinologist point of view

Scheen AJ. Diabetes Res Clin Pract 2020;159:107726.

Strict versus lenient versus poor rate control among patients with atrial fibrillation and heart failure (from the Get With The Guidelines – Heart Failure Program)

Hess PL, Sheng S, Matsouaka R, et al. Am J Cardiol 2020;125:894–900.

Physical therapist clinical practice guideline for the management of individuals with heart failure

Shoemaker MJ, Dias KJ, Lefebvre KM, et al. Phys Ther 2020;100:14–43.

What every cardiologist should know about the 2018 updated adult congenital cardiology guidelines

Dolgner SJ, Buber J, Stout KK, Steinberg ZL. Curr Cardiol Rep 2020;22:24.

2019 ESC Guidelines on diabetes, pre-diabetes, and CV diseases developed in collaboration with the EASD

Cosentino F, Grant PJ, Aboyans V, et al. Eur Heart J 2019;40:3215–7.

Medical therapies for heart failure with preserved ejection fraction

Kjeldsen SE, von Lueder TG, Smiseth OA, et al. Hypertension 2020;75:23–32.

Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions

Liang B, Zhao Y, Gu N. Cardiovasc Diabetol 2020;19:29.

Salt, no salt, or less salt for patients with heart failure?

Khan MS, Jones DW, Butler J. Am J Med 2020;133:32–8.

Hypertension treatment in diabetes: focus on heart failure prevention

Bensimhon HF, Cavender MA. Heart Fail Clin 2019;15:551:563.

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

Verma S, McMurray JJV. Diabetologia. 2018;61:2108–17.

Potential mechanisms of sodium-glucose co-transporter 2 inhibitor-related cardiovascular benefits

Verma S. Am J Cardiol 2019;124 Suppl 1:S36-S44.

Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure

Packer M. Circulation. 2017;136:1548–59.

SGLT‐2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects

Lam CSP, Chandramouli C, Ahooja V, Verma S. J Am Heart Assoc 2019;8:e013389.

Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion

Packer M. Cardiovasc Diabetol. 2019;18:129.

Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes

Handelsman Y. Adv Ther 2019;36:2567–86.

SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice

Wilding J, Fernando K, Milne N, et al. Diabetes Ther 2018;9:1757–73.

Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care

Packer M. European Heart Journal 2020;41:2393–6.

SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials

Inzucchi SE, Zinman B, Wanner C, et al. Diab Vasc Dis Res 2015;12:90–100.

Promising roles of sodium–glucose cotransporter 2 inhibitors in heart failure prevention and treatment

Tanaka A, Node K. Diabetol Int 2020.

Sodium glucose co-transporter 2 inhibitors and heart failure

Ghosh RK, Ghosh GC, Gupta M, et al. Am J Cardiol 2019;124:1790–6.

The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetes

Skelin M, Lucijanic M, Javor E. Eur Heart J 2020;41:325.

Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors

Wojcik C, Warden BA. Curr Cardiol Rep 2019;21:130.

Genetics of dilated cardiomyopathy: practical implications for heart failure management

Rosenbaum AN, Agre KE, Pereira NL. Nat Rev Cardiol 2020;17:286–97.

Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors

Vaduganathan M, Januzzi JL Jr. Am J Cardiol 2019;124 Suppl 1:S20-S27.

Epidemiology and aetiology of heart failure

Ziaeian B, Fonarow GC. Nat Rev Cardiol. 2016;13:368–78.

Dissecting the benefits of sacubitril-valsartan for heart failure

Fernández-Ruiz I. Nat Rev Cardiol 2020;17:71.

Minireview: are SGLT2 inhibitors heart savers in diabetes?

Grubić Rotkvić P, Cigrovski Berković M, Bulj N, Rotkvić L. Heart Fail Rev 2020;25:899–905.

Heart failure with mid-range ejection fraction - a new category of heart failure or still a gray zone

Andronic AA, Mihaila S, Cinteza M. Maedica (Buchar). 2016;11:320–4.

Dapagliflozin for HFrEF - improved outcomes across all ages

Huynh K. Nat Rev Cardiol 2020;17:70–1.

SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function

Maejima Y. Front Cardiovasc Med 2020;6:186.

Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017

Einarson TR, Acs A, Ludwig C, Panton UH. Cardiovasc Diabetol. 2018;17:83.

Targeting age-related pathways in heart failure

Li H, Hastings MH, Rhee J, et al. Circ Res 2020;126:533–51.

Class effects of SGLT2 inhibitors on cardiorenal outcomes

Kluger AY, Tecson KM, Lee AY, et al. Cardiovasc Diabetol 2019;18:99.

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Cefalo CMA, Cinti F, Moffa S, et al. Cardiovasc Diabetol. 2019;18:20.

How do SGLT-2 inhibitors work to prevent heart failure?

Vaduganathan M, Claggett BL, Solomon SD. JACC Heart Fail 2020;8:67–9.

Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes

Garg V, Verma S, Connelly K. Prog Cardiovasc Dis 2019;62:349–57.

Heart failure with preserved ejection fraction: a review of cardiac and noncardiac pathophysiology

Gevaert AB, Boen JRA, Segers VF, Van Craenenbroeck EM. Front Physiol. 2019;10:638.

Lessons from the trials for the desirable effects of sodium glucose co-transporter 2 inhibitors on diabetic cardiovascular events and renal dysfunction

Wakisaka M, Kamouchi M, Kitazono T. Int J Mol Sci 2019;20:5668.

The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure

Verma S, McMurray JJV, Cherney DZI. JAMA Cardiol. 2017;2:939–40.

The sweet spot: heart failure prevention with SGLT2 inhibitors

Vardeny O. Am J Med 2020;133:182–5.

Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes

Cattadori G, Pantanetti P, Ambrosio G. Diabetes Res Clin Pract 2019;157:107835.

Heart failure in patients with type 2 diabetes mellitus: assessment with echocardiography and effects of antihyperglycemic treatments

Iwakura K. J Echocardiogr 2019;17:177–86.

SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?

Sattar N, McLaren J, Kristensen SL, et al. Diabetologia. 2016;59:1333–9.

Treatment of Secondary Mitral Regurgitation in Heart Failure: A Shifting Paradigm in the Wake of the COAPT Trial

US Cardiology Review 2020;14:e06.

Morphine in the Setting of Acute Heart Failure: Do the Risks Outweigh the Benefits?

Cardiac Failure Review 2020;6:e20.

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?

Cardiac Failure Review 2020;6:e21.

Apps and Online Platforms for Patients with Heart Failure

Cardiac Failure Review 2020;6:e14.

Telemedicine, Artificial Intelligence and Humanisation of Clinical Pathways in Heart Failure Management: Back to the Future and Beyond

Cardiac Failure Review 2020;6:e16.

Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

Cardiac Failure Review 2020;6:e19.

Temporary Mechanical Circulatory Support in Acute Heart Failure

Cardiac Failure Review 2020;6:e01.

Asymptomatic Left Ventricle Systolic Dysfunction

European Cardiology Review 2020;15:e13.

COVID-19 Pandemic and Cardiovascular Disease

US Cardiology Review 2020;14:e01.

The Use of App-based Follow-up of Cardiac Implantable Electronic Devices

Cardiac Failure Review 2020;6:e03.

Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure

Cardiac Failure Review 2020;6:e04.

Pulmonary Hypertension in Heart Failure Patients

Cardiac Failure Review 2020;6:e05.

Telemonitoring for the Management of Patients with Heart Failure

Cardiac Failure Review 2020;6:e07.

Heart Failure Treatment by Device

European Cardiology Review 2020;15:e17.

Interatrial Shunting for Treating Acute and Chronic Left Heart Failure

European Cardiology Review 2020;15:e18.

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right

European Cardiology Review 2020;15:e19.

Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure

Cardiac Failure Review 2020;6:e11.

Contemporary Management of Secondary Mitral Regurgitation

European Cardiology Review 2020;15:e22.

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention

US Cardiology Review 2020;14:e04.

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

European Cardiology Review 2019;14(3):201

Unmasking Adenosine: The Purinergic Signalling Molecule Critical to Arrhythmia Pathophysiology and Management

Arrhythmia & Electrophysiology Review 2019;8(4):240–8.

Ivabradine and AF: Coincidence, Correlation or a New Treatment?

Arrhythmia & Electrophysiology Review 2019;8(4):300–3.

Testosterone and the Heart

European Cardiology Review 2019;14(2):103–10

Improving Cardiac Resynchronisation Therapy

Arrhythmia & Electrophysiology Review 2019;8(3):220–7.

Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan

Cardiac Failure Review 2019;5(3):155–61.

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

European Cardiology Review 2019;14(1):23-32

Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment

Cardiac Failure Review 2019;5(3):140–6.

Cardiac Resynchronisation Therapy and Cellular Bioenergetics: Effects Beyond Chamber Mechanics

European Cardiology Review 2019;14(1):33–44

Red Cell Volume Distribution Width as Another Biomarker

Cardiac Failure Review 2019;5(3):176–9.

Chagas Disease and Heart Failure: An Expanding Issue Worldwide

European Cardiology Review 2019;14(2):82–8

Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction

Cardiac Failure Review 2019;5(3):130–2.

State of the Art Structural Interventions in Heart Failure

Cardiac Failure Review 2019;5(3):147–54.

Left Ventricular Assist Device Support Complicates the Exercise Physiology of Oxygen Transport and Uptake in Heart Failure

Cardiac Failure Review 2019;5(3):162–8.

Treating Patients Following Hospitalisation for Acute Decompensated Heart Failure: An Insight into Reducing Early Rehospitalisations

Cardiac Failure Review 2019;5(2):78–82.

Why is Iron Deficiency Recognised as an Important Comorbidity in Heart Failure?

Cardiac Failure Review 2019;5(3):173–5.

Remote Management of Heart Failure: An Overview of Telemonitoring Technologies

Cardiac Failure Review 2019;5(2):86–92.

Baroreflex Activation Therapy for Resistant Hypertension and Heart Failure

US Cardiology Review 2019;13(2):83–7.

Hospice Use Among Patients with Heart Failure

Cardiac Failure Review 2019;5(2):93–8.

Inotropes in Acute Heart Failure: From Guidelines to Practical Use: Therapeutic Options and Clinical Practice

Cardiac Failure Review 2019;5(3):133–9.

Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials

Cardiac Failure Review 2019;5(2):99–105.

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes

Cardiac Failure Review 2019;5(3):169–72.

Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

Cardiac Failure Review 2019;5(2):106–11.

Red Cell Distribution Width as a Biomarker for Heart Failure: Still Not Ready for Prime-Time

Cardiac Failure Review 2019;5(3):180–1.

Diet, the Gut Microbiome and Heart Failure

Cardiac Failure Review 2019;5(2):119–22.

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients

Cardiac Failure Review 2019;5(2):112–8.

Hidden in Heart Failure

European Cardiology Review 2019;14(2):89–96

Cavin-2 Deficiency Attenuates Cardiac Fibrosis and Dysfunction in Pressure-overloaded Hearts

European Cardiology Review 2018;13(2):120.

Exercise Training and Heart Failure: A Review of the Literature

Cardiac Failure Review 2019;5(1):57–61.

Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy

European Cardiology Review 2018;13(2):121.

Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip

Interventional Cardiology Review 2019;14(1):45–7

The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy

European Cardiology Review 2018;13(2):125.

The Evolving Role of Catheter Ablation in Patients With Heart Failure and AF

Arrhythmia & Electrophysiology Review 2019;8(1):47–53.

TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4

European Cardiology Review 2018;13(2):126.

The Role of p53 Localised in Cytosol and Mitochondria During Reprogramming to iPS Cells

European Cardiology Review 2018;13(2):127.

The Mechanism of Hey2 Expression in Cardiac Development

European Cardiology Review 2018;13(2):128.

Relationship Between VEGF-C Levels and All-cause Mortality in Patients with Chronic Heart Failure

European Cardiology Review 2018;13(2):129.

A PRMT5 Selective Inhibitor EPZ015666 Suppressed TAC-induced Left Ventricular Dysfunction

European Cardiology Review 2018;13(2):130.

The New Heart Failure Association Definition of Advanced Heart Failure

Cardiac Failure Review 2019;5(1):5–8.

Ultrafiltration in Acute Heart Failure

Cardiac Failure Review 2019;5(1):9–18.

Choosing Between Left Ventricular Assist Devices and Biventricular Assist Devices

Cardiac Failure Review 2019;5(1):19–23.

Focusing on Referral Rather than Selection for Advanced Heart Failure Therapies

Cardiac Failure Review 2019;5(1):24–6.

Haemodynamic Monitoring Devices in Heart Failure: Maximising Benefit with Digitally Enabled Patient Centric Care

Arrhythmia & Electrophysiology Review 2018;7(4):294–8.

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs

Cardiac Failure Review 2019;5(1):27–30.

Left Ventricular Ejection Fraction in Heart Failure

European Cardiology Review 2018;13(2):91–2.

Subclinical Left Ventricular Dysfunction During Chemotherapy

Cardiac Failure Review 2019;5(1):31–6.

Catheter Ablation for Atrial Fibrillation in Systolic Heart Failure Patients : Stone by Stone, a CASTLE

Arrhythmia & Electrophysiology Review 2018;7(4):265–72.

Natriuretic Peptides in Chronic Heart Failure

Cardiac Failure Review 2019;5(1):44–9.

Understanding Iron Deficiency in Heart Failure: Clinical Significance and Management

US Cardiology Review 2018;12(2):110–2.

Biomarkers in Routine Heart Failure Clinical Care

Cardiac Failure Review 2019;5(1):50–6.

Amyloid Heart Disease

US Cardiology Review 2018;12(2):113–8.

Heart Failure in Sub-Saharan Africa

Cardiac Failure Review 2018;4(1):21–4.

Premature Ventricular Complex-induced Cardiomyopathy

Arrhythmia & Electrophysiology Review 2018;7(2):128–34.

Optimising Heart Failure Therapies in the Acute Setting

Cardiac Failure Review 2018;4(1):38–42.

Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes

European Cardiology Review 2018;13(1):42–5.

What is Heart Failure with Mid-range Ejection Fraction? A New Subgroup of Patients with Heart Failure

Cardiac Failure Review 2018;4(1):6–8.

Advances in Imaging and Heart Failure: Where are we Heading?

Cardiac Failure Review 2018;4(2):73–7.

Heart Failure with Mid-Range Ejection Fraction and How to Treat It

Cardiac Failure Review 2018;4(1):9–13.

Imaging of Valvular Heart Disease in Heart Failure

Cardiac Failure Review 2018;4(2):78–86.

Left Ventricular Dysfunction in the Setting of Takotsubo Cardiomyopathy: A Review of Clinical Patterns and Practical Implications

Cardiac Failure Review 2018;4(1):14–20.

Heart–brain Interactions in Heart Failure

Cardiac Failure Review 2018;4(2):87–91.

Pharmacological Interventions Effective in Improving Exercise Capacity in Heart Failure

Cardiac Failure Review 2018;4(1):25–7.

Calming the Nervous Heart: Autonomic Therapies in Heart Failure

Cardiac Failure Review 2018;4(2):92–8.

Iron Therapy in Heart Failure: Ready for Primetime?

Cardiac Failure Review 2018;4(1):28–32.

Metabolic Modulation of Cardiac Metabolism in Heart Failure

Cardiac Failure Review 2018;4(2):99–103.

Ablation for Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction

Cardiac Failure Review 2018;4(1):33–7.

Frailty in Heart Failure: Implications for Management

Cardiac Failure Review 2018;4(2):104–6.

Ambulatory Intra Aortic Balloon Pump in Advanced Heart Failure

Cardiac Failure Review 2018;4(1):43–5.

Exercise Training in Heart Failure Patients With Persistent Atrial Fibrillation: a Practical Approach

Cardiac Failure Review 2018;4(2):107–11.

Bromocriptine for the Treatment of Peripartum Cardiomyopathy

Cardiac Failure Review 2018;4(1):46–9.

Postpartum Cardiomyopathy and Considerations for Breastfeeding

Cardiac Failure Review 2018;4(2):112–8.

Identification and Treatment of Central Sleep Apnoea: Beyond SERVE-HF

Cardiac Failure Review 2018;4(1):50–3.

Letter to the Editor: His Bundle Pacing: A New Frontier in the Treatment of Heart Failure

Arrhythmia & Electrophysiology Review 2018;7(3):218.

A Review of Plant-based Diets to Prevent and Treat Heart Failure

Cardiac Failure Review 2018;4(1):54–61.

Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All

Arrhythmia & Electrophysiology Review 2018;7(2):84–90.

Treatment of Atrial Fibrillation in Patients with Coexisting Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?

Arrhythmia & Electrophysiology Review 2018;7(2):91–4.

His Bundle Pacing: A New Frontier in the Treatment of Heart Failure

Arrhythmia & Electrophysiology Review 2018;7(2):103–10.

Recognition, Diagnosis, and Management of Heart Failure with Preserved Ejection Fraction

US Cardiology Review 2018;12(1):8–12.

Sudden Cardiac Death and Arrhythmias

Arrhythmia & Electrophysiology Review 2018;7(2):111–7.

Cardiovascular Risk Management Targeting Inflammation in Addition to Lipid-lowering Therapy

European Cardiology Review 2017;12(2):88

Nobiletin a Citrus Flavonoid, Exerts Additional Effects with Angiotensin II Receptor Blocker on Systolic Function in Salt-sensitive Dahl Rats

European Cardiology Review 2017;12(2):92.

Whatever Happened to Measuring Ventricular Contractility in Heart Failure?

Cardiac Failure Review 2017;3(2):79–82.

Cardiac Resynchronization is Associated with Reduction in the Rate of ICD Therapies, While Improves Ventricular Function

European Cardiology Review 2017;12(2):93.

Natriuretic Peptide-based Screening and Prevention of Heart Failure

Cardiac Failure Review 2017;3(2):83–5.

Effects of Pharmacotherapy for Smoking Cessation on LOX Index, a Cardiovascular Risk Marker

European Cardiology Review 2017;12(2):96.

The Future Role of Cardio-oncologists

Cardiac Failure Review 2017;3(2):140–2.

5-Year Outcomes After Implementation of Optimal Medical Therapy in General Practice Using Liaison Critical Pathway for Secondary Prevention of Coronary Artery Disease: An Observational Study

European Cardiology Review 2017;12(2):98.

Sleep-Disordered Breathing During Congestive Heart Failure: To Intervene or Not to Intervene?

Cardiac Failure Review 2017;3(2):134–9

A Risk Score to Predict the Absence of Left Ventricular Reverse Remodelling: Implications for the Timing of ICD Implantation in Primary Prevention

European Cardiology Review 2017;12(2):99.

Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey

Cardiac Failure Review 2017;3(2):130–3.

Does Angiotensin Receptor Neprilysin Inhibitor (ARNI) Improve Functional Capacity Assessed by 6 Minutes Walking Test?

European Cardiology Review 2017;12(2):100.

Applying Heart Failure Management to Improve Health Outcomes: But WHICH One?

Cardiac Failure Review 2017;3(2):113–5.

The Impact of an Atrial Septal Defect on Hemodynamics in Patients With Heart Failure

US Cardiology Review 2017;11(2):72–4.

Secondary Prevention in Patients with Non Valvular Atrial Fibrillation and Previous Stroke. Is It Possible to Have an Appropriate INR Control?

European Cardiology Review 2017;12(2):103.

Dilemmas in the Dosing of Heart Failure Drugs: Titrating Diuretics in Chronic Heart Failure

Cardiac Failure Review 2017;3(2):108–12.

New Drugs for the Treatment of Heart Failure

US Cardiology Review 2017;11(2):62–6.

Consensus is Possible: Initiation and Exchange of Oral Anticoagulants in Non-valvular Atrial Fibrillation, According to a Territorial Protocol in a Period of Time

European Cardiology Review 2017;12(2):104.

The Role of Automated 3D Echocardiography for Left Ventricular Ejection Fraction Assessment

Cardiac Failure Review 2017;3(2):97–101.

Role of Testosterone in the Treatment of Cardiovascular Disease

European Cardiology Review 2017;12(2):83–7

A Novel Target Molecule of Nobiletin Derived from Citrus Peels has a Therapeutic Potency Against the Development of Heart Failure

European Cardiology Review 2017;12(2):105.

Hypertension and Frailty Syndrome in Old Age: Current Perspectives

Cardiac Failure Review 2017;3(2):102–7.

Inflammation Revisited: Atherosclerosis in The Post-CANTOS Era

European Cardiology Review 2017;12(2):89–91

Curcumin Analogue GO-Y030 Significantly Improves Pressure Overload-induced Heart Failure in Vivo

European Cardiology Review 2017;12(2):106.

Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure

Cardiac Failure Review 2017;3(2):122–9.

The Inhibitory Effects of Curcumin Glucuronide on p300-HAT Activity and Hypertrophic Phenylephrine-Induced Responses in Cardiomyocytes

European Cardiology Review 2017;12(2):107.

The Prognostic Role of Tissue Characterisation using Cardiovascular Magnetic Resonance in Heart Failure

Cardiac Failure Review 2017;3(2):86–96.

A Transcriptional Co-activator, p300 is Involved in the Epigenetic Gene Activation on Hypertrophic Response Gene Promoters in Heart Failure

European Cardiology Review 2017;12(2):110.

Highlights Of The 2016 European Society Of Cardiology Guidelines On Heart Failure

European Cardiology Review 2017;12(2):76–7

Analysis of Factors Associated with Smoking Relapse

European Cardiology Review 2017;12(2):111.

Impact on Patient Care: The 2016 European Heart Failure Guidelines

European Cardiology Review 2017;12(2):78–9

Influence of Race in the Association of Diabetes and Heart Failure

US Cardiology Review 2018;12(1):17–21.

Hypertrophic Cardiomyopathy in Athletes

European Cardiology Review 2017;12(2):80–2

Cardiac Atrophy and Heart Failure In Cancer

Cardiac Failure Review 2017;3(1):62–5

Is Medication Titration in Heart Failure too Complex?

Cardiac Failure Review 2017;3(1):25–32.

How to Improve Adherence to Life-saving Heart Failure Treatments with Potassium Binders

Cardiac Failure Review 2017;3(1):33–9

Practical Applications for Single Pill Combinations in the Cardiovascular Continuum

Cardiac Failure Review 2017;3(1):40–5.

A Review of Image-guided Approaches for Cardiac Resynchronisation Therapy

Arrhythmia & Electrophysiology Review 2017;6(2):69–74.

Is There a Future for Remote Cardiac Implantable Electronic Device Management?

Arrhythmia & Electrophysiology Review 2017;6(3):109–10.

Value of Telemonitoring and Telemedicine in Heart Failure Management

Cardiac Failure Review 2017;3(2):116–21.

Heart Failure in Patients with Diabetes Mellitus

Cardiac Failure Review 2017;3(1):52–5.

Chronic Heart Failure Care Planning: Considerations in Older Patients

Cardiac Failure Review 2017;3(1):46–51.

Cancer and Heart Failure: Understanding the Intersection

Cardiac Failure Review 2017;3(1):66–70.

Cardiac Toxicity of Cancer Chemotherapy

US Cardiology Review 2017;11(1):20–4

Neurohormonal Blockade in Heart Failure

Cardiac Failure Review 2017;3(1):19–24.

Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease

Cardiac Failure Review 3(1):56–61.

Global Public Health Burden of Heart Failure

Cardiac Failure Review 2017;3(1):7–11.

Ventricular–Arterial Coupling in Chronic Heart Failure

Cardiac Failure Review 2017;3(1):12–8.

Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?

Cardiac Failure Review 2016;2(1):47–50

Chagas Heart Failure in Patients from Latin America

Cardiac Failure Review 2016;2(2):90–4

Nitrates as a Treatment of Acute Heart Failure

Cardiac Failure Review 2016;2(1):51–5

Impact of Exercise Training on Peak Oxygen Uptake and its Determinants in Heart Failure with Preserved Ejection Fraction

Cardiac Failure Review 2016;2(2):95–101

Shock Management for Cardio-surgical Intensive Care Unit Patient: The Silver Days

Cardiac Failure Review 2016;2(1):56–62

Haemodynamics of Heart Failure With Preserved Ejection Fraction: A Clinical Perspective

Cardiac Failure Review 2016;2(2):102–5

Pacing and Defibrillators in Complex Congenital Heart Disease

Arrhythmia & Electrophysiology Review 2016;5(1):57–64

Cognitive Decline in Heart Failure: More Attention is Needed

Cardiac Failure Review 2016;2(2):106–9

Periodic Repolarisation Dynamics: A Natural Probe of the Ventricular Response to Sympathetic Activation

Arrhythmia & Electrophysiology Review 2016;5(1):31–6

Depression in Patients with Heart Failure: Is Enough Being Done?

Cardiac Failure Review 2016;2(2):110–2

Post-extrasystolic Potentiation: Link between Ca2+ Homeostasis and Heart Failure?

Arrhythmia & Electrophysiology Review 2016;5(1):20–6

A Clinical Perspective on Sudden Cardiac Death

Arrhythmia & Electrophysiology Review 2016;5(3):177–82

Complementary and Synergic Role of Combined Beta-blockers and Ivabradine in Patients with Chronic Heart Failure and Depressed Systolic Function: A New Therapeutic Option?

Cardiac Failure Review 2016;2(2)130–6

Atrial Fibrillation and Heart Failure: How Should We Manage Our Patients?

Arrhythmia & Electrophysiology Review 2016;5(3):162-3

ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy

Arrhythmia & Electrophysiology Review 2016;5(3):188–96

The Role of Ivabradine and Trimetazidine in the New ESC HF Guidelines

Cardiac Failure Review, 2016;2(2):123–9

Role of the Thyroid System in the Dynamic Complex Network of Cardioprotection

European Cardiology Review 2016;11(1):36–42

The European Heart Rhythm Association: A Myriad of Benefits and Privileges

Arrhythmia & Electrophysiology Review 2016;5(2):82

The Mechanism of Action of LCZ696

Cardiac Failure Review 2016;2(1):40–6

Pharmacologic Strategies for Management of Pulmonary Arterial Hypertension

US Cardiology Review 2016;10(2):78–84

Cardiac Rehabilitation in Patients with Heart Failure – New Perspectives in Exercise Training

Cardiac Failure Review 2016;2(1):63–8

The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure

Cardiac Failure Review, 2016;2(2):115–22

The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia

Arrhythmia & Electrophysiology Review 2016;5(1):45–9

Current Status of the Left Ventricular Assist Device as a Destination Therapy

US Cardiology Review 2016;10(2):85–90

Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure

Cardiac Failure Review 2016;2(1):8–13

Should We Let Sleeping Dogs Lie? Controversies of Treating Central Sleep Apnoea in HFrEF Following the SERVE-HF Study

Cardiac Failure Review 2016;2(2):113–4

Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective

Cardiac Failure Review 2016;2(1):14–9

Transitional Care to Reduce Heart Failure Readmission Rates in South East Asia

Cardiac Failure Review 2016;2(2):85–9

Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?

Cardiac Failure Review 2016;2(1):35–9

What the General Practitioner Needs to Know About Their Chronic Heart Failure Patient

Cardiac Failure Review 2016;2(2):79–84

The Diagnosis and Clinical Implications of Interatrial Block

European Cardiology Review 2015;10(1):54–9

Focused Ultrasound in the Emergency Department for Patients with Acute Heart Failure

Cardiac Failure Review 2015;1(2):83–6

Sudden Cardiac Death in Athletes

European Cardiology Review 2015;10(1):48–53

Takotsubo Syndrome – Stress-induced Heart Failure Syndrome

European Cardiology Review 2015;10(2):83–8

Managing Heart Failure Patients with Multivessel Disease – Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention

Cardiac Failure Review 2015;1(2):118–22

Home Orthostatic Training in Elderly Patients with Vasovagal Syncope – A Prospective Randomised Controlled Trial

European Cardiology Review 2015;10(2):123–7

The Entirely Subcutaneous Defibrillator – A New Generation and Future Expectations

Arrhythmia & Electrophysiology Review 2015;4(2):116–21

Sleep-disordered Breathing in Heart Failure

European Cardiology Review 2015;10(2):89–94

Developments in Cardiac Resynchronisation Therapy

Arrhythmia & Electrophysiology Review 2015;4(2):122–8

Cardiac Amyloid – An Update

European Cardiology Review 2015;10(2):113–7

Assessment of Left Ventricular Diastolic Function by Doppler Echocardiography

Cardiac Failure Review 2015;1(2):87–9

A Practical Clinical Approach to the Diagnosis and Treatment of Patients with Pulmonary Hypertension

European Cardiology Review 2015;10(2):102–7

Biomarker Guided Therapy in Chronic Heart Failure

Cardiac Failure Review 2015;1(2):96–101

Sudden Cardiac Death Risk Stratification – An Update

European Cardiology Review 2015;10(2):118–22

Fluid Management in Patients with Chronic Heart Failure

Cardiac Failure Review 2015;1(2):90–5

Decompensated Heart Failure in Pregnancy

Cardiac Failure Review 2016;2(1):20–6

The Key Roles for the Nurse in Acute Heart Failure Management

Cardiac Failure Review 2015;1(2):123–7

Novel Imaging Techniques for Heart Failure

Cardiac Failure Review 2016;2(1):27–34

Patient Self-management in Chronic Heart Failure – Establishing Concordance Between Guidelines and Practice

Cardiac Failure Review 2015;1(2):128–31

Promising New Therapies in Heart Failure: Ivabradine and the Neprilysin Inhibitors

US Cardiology Review 2016;10(1):8–13

Role of Cardiac Troponin Levels in Acute Heart Failure

Cardiac Failure Review 2015;1(2):102–6

Takotsubo Cardiomyopathy

European Cardiology Review 2015;10(1):25–30

Biomarkers in Acute Heart Failure – Cardiac And Kidney

Cardiac Failure Review 2015;1(2):107–11

What is Takotsubo (Stress) Cardiomyopathy?

European Cardiology Review 2015;10(1):6–8

Cellular Communications in the Heart

Cardiac Failure Review 2015;1(2):64–8

Risk Stratification in Hypertrophic Cardiomyopathy

European Cardiology Review 2015;10(1):31–6

How to Improve Time to Diagnosis in Acute Heart Failure – Clinical Signs and Chest X-ray

Cardiac Failure Review 2015;1(2):69–74

Chemotherapy-related Cardiomyopathy

European Cardiology Review 2015;10(1):19–24

Metabolic Therapy in Heart Failure

Cardiac Failure Review 2015;1(2):112–7

Diuretic Therapy in Heart Failure – Current Approaches

European Cardiology Review 2015;10(1):42–7

Shock Management for Cardio-surgical ICU Patients – The Golden Hours

Cardiac Failure Review 2015;1(2):75–82

The Role of Aldosterone Blockade in Patients with Heart Failure Due to Systolic Left Ventricular Dysfunction

US Cardiology 2004;1(1):1–6

Update on Cardiac Resynchronisation Therapy for Heart Failure

European Cardiology Review 2014;9(2):100–3

Treatment of Chronic Heart Failure

US Cardiology 2006;3(1):1–5

Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides — The Case for Soluble ST2

European Cardiology Review 2015;10(1):37–41

Wall Motion Tracking and Activation Imaging - Latest Developments and Applications for Patients with Heart Failure

European Cardiology 2012;8(1):51-5

Cardiac Resynchronisation Therapy and Heart Failure: Perspective from 5P Medicine

Cardiac Failure Review 2015;1(1):35–7

Pharmacological Treatment of Patients with Chronic Systolic Heart Failure

European Cardiology Review 2014;9(1):43–8

Pulmonary Oedema—Therapeutic Targets

Cardiac Failure Review 2015;1(1):38-45

Diabetes Mellitus and Heart Failure

European Cardiology Review 2014;9(1):37–42

The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes – A review of the Epidemiology and Outcomes

Cardiac Failure Review 2015;1(1):8–10

Mitral Regurgitation – A Multidisciplinary Challenge

European Cardiology Review 2014;9(1):49–53

The Management of Heart Failure with Preserved Ejection Fraction

Cardiac Failure Review 2015;1(1):11–5

Ventricular Assist Devices – Evolution of Surgical Heart Failure Treatment

European Cardiology Review 2014;9(1):54–8

Sleep-disordered Breathing in Heart Failure – Current State of the Art

Cardiac Failure Review 2015;1(1):16–24

Short QT Syndrome – Review of Diagnosis and Treatment

Arrhythmia & Electrophysiology Review 2014;3(2):76–9

Gaps in the Heart Failure Guidelines

Cardiac Failure Review 2015;1(1):50–5

Left Ventricular Assist Devices in the Management of Heart Failure

Cardiac Failure Review 2015;1(1):25–30

Cardiac or Other Implantable Electronic Devices and Sleep-disordered Breathing – Implications for Diagnosis and Therapy

Arrhythmia & Electrophysiology Review 2014;3(2):116–9

Management of Heart Failure in Patients Nearing the End of Life - There is So Much More To Do

Cardiac Failure Review 2015;1(1):31–4

Can we Modulate the Autonomic Nervous System to Improve the Life of Patients with Heart Failure? The Case of Vagal Stimulation

Arrhythmia & Electrophysiology Review 2014;3(2):120–2

Assessment for Exercise Prescription in Heart Failure

Cardiac Failure Review 2015;1(1):46–9

Remote Monitoring for Follow-up of Patients with Cardiac Implantable Electronic Devices

Arrhythmia & Electrophysiology Review 2014;3(2):123–8

Cardiovascular Innovation Pipeline

RadcliffeCardiology.com, August 2014.

Sudden Unexplained Death – Treating the Family

Arrhythmia & Electrophysiology Review 2014;3(3):156–60

Cardiac Resynchronisation Therapy or MitraClip® Implantation for Patients with Severe Mitral Regurgitation and Left Bundle Branch Block?

Arrhythmia & Electrophysiology Review 2014;3(3):190–3

The Brugada Syndrome – Diagnosis, Clinical Implications and Risk Stratification

European Cardiology Review 2014;9(2):82–7

Gaps in the Heart Failure Guidelines

European Cardiology Review 2014;9(2):104–9

A Critical Reappraisal of the Current Clinical Indications to Cardiac Resynchronisation Therapy

Arrhythmia & Electrophysiology Review 2013;2(2):91-4

Use of Cardiac Resynchronisation Therapy - Change of Clinical Settings

Arrhythmia & Electrophysiology Review 2014;3(1):20-4

Current Evidence and Recommendations for Cardiac Resynchronisation Therapy

Arrhythmia & Electrophysiology Review 2014;3(1):9-14

Acute Heart Failure Syndromes

Baroreflex Sensitivity Assessment - Latest Advances and Strategies

US Cardiology 2012;9(1):22-5

Cardiac Transplantation - Status in 2011

European Cardiology 2011;7(4):273–9

Foreword

US Cardiology 2005;2(1):20

Foreword

US Cardiology 2005;2(1):34

Foreword

US Cardiology 2005;2(1):77

Implantable Cardiac Devices in the Treatment of Arrhythmias and Congestive Heart Failure

US Cardiology 2012;9(2):99-104

Managing Hyponatraemia in Heart Failure

European Cardiology 2008;4(2):39–41

Gazing through the Crystal Ball of Science - Cardiovascular Disease in 2100

US Cardiology 2012;9(2):86-9

Heart Failure with Preserved Ejection Fraction - A Review

US Cardiology 2012;9(2):90-5

Spontaneous Coronary Artery Dissection Presenting with Stroke

American Heart Hospital Journal 2011;9(2):125-7

Acute Coronary Syndrome in Pre- and Post-partum Women - A Review

Interventional Cardiology Review 2013;8(1):8–13

Body Surface Electrocardiographic Mapping for Non-invasive Identification of Arrhythmic Sources

Arrhythmia & Electrophysiology Review 2013;2(1):16-22

Preventing Sudden Cardiac Death in Patients with Ischaemic Cardiomyopathy

European Cardiology 2012;8(2):134-8

Telemonitoring in Patients with Heart Failure - Lessons from Recent Randomised Multicentre Trials

European Cardiology 2012;8(2):84-7

Measuring Left Ventricular Ejection Fraction - Techniques and Potential Pitfalls

European Cardiology 2012;8(2):108-14

Assessing Acute Decompensated Heart Failure - Strategies and Tools

European Cardiology 2012;8(2):128-33

Heart Failure with Preserved Ejection Fraction - A Review

European Cardiology 2012;8(3):186–91

Catheter Ablation of Atrial Fibrillation - Techniques and Technology

Arrhythmia & Electrophysiology Review, 2012;1(1):29–33

Defibrillation Testing During Defibrillator Implantation

Arrhythmia & Electrophysiology Review 2012;1(1):51–3

Adipose-Derived Regenerative Cells for the Treatment of Patients with Non-revascularisable Ischaemic Cardiomyopathy - The PRECISE Trial

Interventional Cardiology 2012;7(2):77–80

Using Natriuretic Peptides to 'Guide' Therapy in Heart Failure

European Cardiology 2012;8(1):36-9

Sleep-disordered Breathing and Heart Failure - Insights from Speckle Tracking Echocardiography

European Cardiology 2012;8(1):40-3

The Evolution of Ventricular Assist Devices and the HeartWare® Ventricular Assist System

European Cardiology 2012;8(1):32-5

Exercise Capacity in Chronic Heart Failure

US Cardiology 2012;9(1):57-60

The Role of Cardiac Rehabilitation in Heart Failure Patients

US Cardiology 2012;9(1):61-5

Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnea in Heart Failure

US Cardiology 2012;9(1):53-6

Breakthrough Regenerative Cardiopoietic Stem Cells and Related Technologies in the Field of Cardiovascular Medicine - From Bench to Bedside

Interventional Cardiology 2012;7(1):14–6

The Use of an Absorbable Microporous Polysaccharide Hemosphere Haemostat (AristaAH) in Ventricular Assist Device Implant and Cardiac Transplantation Procedures

European Cardiology 2011;8(2):125-7

New Developments in the Management of Chronic Heart Failure

US Cardiology 2005;2(1):210-2

Heart Failure in African-Americans

US Cardiology 2005;2(1):196-200

Improving Care for African-American Heart Failure Patients

US Cardiology 2006;3(1):86–9

Viability Studies - Comparison of Techniques

American Heart Hospital Journal 2011;9(2):107-11

Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnoea in Heart Failure

European Cardiology 2012;8(1):44-7

Future Directions in Cardiac Surgery - Part II

American Heart Hospital Journal 2011;9(1):15-8

Diastolic Heart Failure - Are Treatment Options Available?

European Cardiovascular Disease 2006;2(2):73–5

Sudden Cardiac Death in Children and Adolescents

US Cardiology 2006;3(2):1–4

The Use of B-type Natriuretic Peptide in Clinical Practice

European Cardiovascular Disease 2006;2(1):37–9

Echocardiography in the Detection and Monitoring of Heart Failure

European Cardiovascular Disease 2006;2(1):53–6

The Role of Aldosterone Blockade in Patients with Heart Failure Due to Systolic Left Ventricular Dysfunction

US Cardiology 2004;1(1):129–35

NT-proBNP — A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure

US Cardiology 2004;1(1):148–9

Long-term Circulatory Support — The Left Ventricular Assist System for Advanced Heart Failure

US Cardiology 2004;1(1):145–7

Current Thinking in Acute Congestive Heart Failure and Pulmonary Edema

US Cardiology 2004;1(1):136–40

Anti-platelet Therapy for Congestive Heart Failure - Is there Enough Evidence for More Aggressive Strategies?

US Cardiology 2004;1(1):150–2

Unrecognized Volume Overload in Congestive Heart Failure

US Cardiology 2004;1(1):141–4

Inhibition of the Late Sodium Current with Ranolazine - A New Cardioprotective Mechanism

European Cardiology 2008;4(2):46–8

Comparison of B-type Natriuretic Peptide and N-terminal proBNP in Daily Clinical Practice

European Cardiology 2008;4(2):35–8

Managing Hyponatremia in Heart Failure

US Cardiology 2008;5(1):57–60

Cardiac Iodine-123 Metaiodobenzylguanidine Imaging for Risk Stratification in Heart Failure Patients

European Cardiology 2008;4(2):42–5

B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes

European Cardiovascular Disease 2007;3(2):22–3

Tako-tsubo Cardiomyopathy in Patients with Intracerebral Haemorrhage

European Cardiovascular Disease 2006;2(2):70–2

Amino-terminal Pro-brain Natriuretic Peptide Testing - Recent Lessons Learned

European Cardiovascular Disease 2006;2(2):20–4

Treatment of Chronic Heart Failure

US Cardiology 2006;3(1):90–2

Amino-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) Testing - Recent Lessons Learned

US Cardiology 2006;3(1):1–5

Monitoring Heart Failure using an Implantable Device Measuring Intrathoracic Impedance - Technical and Clinical Overview

European Cardiology 2005;1(1):62-5

The Role of Beta Blockade in Heart Failure

European Cardiology 2005;1(1):58-60

Baroreflex Sensitivity Assessment - Latest Advances and Strategies

European Cardiology 2011;7(2):89–92

Chronic Mechanical Circulatory Support for Patients with End-stage Heart Failure as a Definitive Treatment Option

European Cardiology 2010;6(4):22–5

Amino-terminal Pro-B-type Natriuretic Peptide Testing - Past, Present, and Future Applications

US Cardiology 2008;5(1):61–5

The Surgeon's Role in Resynchronization Therapy

US Cardiology 2008;5(1):70–1

Risk Stratification of Patients with Acute Coronary Syndrome and Congestive Heart Failure

US Cardiology 2007;4(2):35–6

Mechanical Circulatory Support in Heart Failure

US Cardiology 2011;8(1):47–51

Multidetector-row Computed Tomography in the Assessment of Coronary Artery Disease - New Techniques and Insights

European Cardiology 2010;6(2):43–7

Myocardial Metabolic Imaging in the Clinical Setting

European Cardiology 2009;5(1):15–8

Non-calcified Coronary Plaque in an Asymptomatic Physician

American Heart Hospital Journal 2009;7(1):62

Controversies in Implantable Cardioverter-defibrillator Therapy

European Cardiology 2011;7(3):199–202

Non-pharmacological Management and Patient Education in Heart Failure Patients

European Cardiovascular Disease 2006;2(1):108–10

Natriuretic Peptides - Addressing the Dilemma of Heart Failure Management

European Cardiology 2011;7(2):104–7

Ion Channel Remodelling in Atrial Fibrillation

European Cardiology 2011;7(2):97–103

Galectin-3 in Heart Failure - Linking Fibrosis, Remodeling, and Progression

US Cardiology 2010;7(1):67–70

Gender Differences in the Acute HEArt Database Registry

US Cardiology 2009;6(2):64–6

Histopathological Changes and Clinical Implications in Patients with Hypertrophic Cardiomyopathy

European Cardiology 2010;6(2):88–90

Long-term Circulatory Support - The Left Ventricular Assist System for Advanced Heart Failure

Clinical and Diagnostic Aspects of Takotsubo Cardiomyopathy

Asia-Pacific Cardiology 2011;3(1):60-3

Telemonitoring in Heart Failure Rehabilitation

European Cardiology 2011;7(1):66–9

Innovative Cardiac Diagnostics - Key to the Total Management of Cardiovascular Disease

Asia-Pacific Cardiology 2011;3(1):19–29

Heart Failure in African-Americans

Galectin-3 in Heart Failure - Linking Fibrosis, Remodeling, and Progression

European Cardiology 2010;6(2):33–6

The Non-Invasive Cardiac System - Cardiac Surveyor (NICaS CS) - An Ambulatory Tool for the Diagnosis of Asymptomatic Coronary Artery Disease

The SynCardia Temporary Total Artificial Heart - Evolving Clinical Role and Future Status

US Cardiology 2011;8(1):39–46

Progression of Low-pressure to Acute Classic Cardiac Tamponade - A Diagnostic Dilemma in the Setting of Spontaneous Left Ventricular Rupture

American Heart Hospital Journal 2010;8(2):133–5

Right Ventricular Myxoma Obstructing the Outflow Tract

American Heart Hospital Journal 2010;8(2):118–21

Risk Stratification in Post-myocardial Infarction Patients

European Cardiology 2010;6(3):22–6

Symptomatic Calcific Constrictive Pericarditis Presenting Years After Presumed Resolved Inflammatory Heart Disease

American Heart Hospital Journal 2010;8(2):130–2

The Digital Ballistocardiograph

US Cardiology 2009;6(2):115–9

Devices for Transcatheter Haemodynamic Support for Left Heart Failure

Interventional Cardiology 2010;5:16–9

Diagnosing Heart Failure – Experience and ‘Best Pathways’

European Cardiology 2010;6(3):10–2

Echocardiographic Assessment of Diastolic Heart Failure

European Cardiology 2010;6(3):13–7

Echocardiographic Measurement of Mechanical Dyssynchrony in Heart Failure and Cardiac Resynchronization Therapy

US Cardiology 2010;7(1):24–32

Electrocardiographic Criteria in Tako-Tsubo Cardiomyopathy - Is There Added Certainty in a Diagnosis Per Exclusionem?

American Heart Hospital Journal 2009;7(2):130–5

Cardiac Resynchronisation Therapy in Chronic Heart Failure

European Cardiology 2005;1(1):1-5

Cardiac Resynchronization Therapy - Evolving Strategies to Enhance Response

US Cardiology 2010;7(1):61-6

Central Sleep Apnea in Heart Failure

US Cardiology 2009;6(2):72–8

Monitoring Heart Failure using an Implantable Device Measuring Intrathoracic Impedance - Technical and Clinical Overview

European Cardiology 2005;1(1):1-4

New Echocardiographic Modalities in the Detection and Monitoring of Heart Failure -The Clinical Potential of Speckle-tracking Technology

European Cardiovascular Disease 2007;3(1):115–8

Amino-terminal Pro-B-type Natriuretic Peptide Testing - Past, Present, and Future Applications

Asia-Pacific Cardiology 2008;2(1):69-73

Atrial Fibrillation in Heart Failure Patients

European Cardiology 2009;5(1):41–5

Atrial Fibrillation in the Failing Heart - A Clinical Review

European Cardiology 2010;6(1):75–9

Beyond the Apnoea-Hypopnoea Index - Prognostic Value of Other Elements of Polysomnography to Describe Sleep-disordered Breathing in Heart Failure

European Cardiology 2009;5(2):53–6

Blood Volume Analysis Coupled with Ultrafiltration in the Management of Congestive Heart Failure - Guided Therapy to Achieve Euvolemia

US Cardiology 2010;7(1):72–5

Cardiac Resynchronisation Therapy - Evolving Strategies to Enhance Response

European Cardiology 2010;6(1):83–7

Phosphodiesterase-5 Inhibition in Chronic Heart Failure - An Emerging Therapeutic Opportunity

European Cardiology 2008;4(1):28–30

Risk Stratification of Patients with Acute Coronary Syndrome and Congestive Heart Failure

Asia-Pacific Cardiology 2007;1(1):20-1

Current Perspective for Cardiac Magnetic Resonance Imaging in Heart Failure

Asia-Pacific Cardiology 2007;1(1):27-8

Developments in the Management of Atrial Arrhythmias in Congestive Heart Failure

Asia-Pacific Cardiology 2007;1(1):46-8

Exercise Therapy for the Failing Heart - Harmful or Helpful?

US Cardiology 2009;6(1):56–60

Ultrafiltration in the Management of Heart Failure

US Cardiology 2008;5(1):66–9

Heart Failure with Preserved Ejection Fraction

European Cardiology 2008;4(1):31–3

Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death

European Cardiology 2010;6(3):92–6

Statin Therapy in Patients with Diastolic Heart Failure - Time for a Large, Randomised Study?

European Cardiovascular Disease 2007;3(1):120–2

Stress Echocardiography - Current Status

European Cardiology 2005;1(1):1-5

Sudden Cardiac Death—A Current Perspective

US Cardiology 2005;2(1):1-7

Optimizing Clinical Outcomes in Acute Decompensated Heart Failure

US Cardiology 2009;6(1):50–4

Erythropoietin in Congestive Heart Failure

US Cardiology 2006;3(2):122–4

3-D Echocardiography - An Emerging Giant in the Treatment of Heart Failure

US Cardiology 2007;4(1):50–2

An Update on N-terminal Pro-Brain-type Natriuretic Peptide for Risk Stratification in Chronic Heart Failure

European Cardiovascular Disease 2007;3(1):35–8

Anti-platelet Therapy for Congestive Heart Failure — Is There Enough Evidence for More Aggressive Strategies?

US Cardiology 2004;1(1):1–6

Atrial Fibrillation in the Setting of Heart Failure

European Cardiology 2010;6(2 Suppl):13–6

B-type Natriuretic Peptides in the Management of Acute Heart Failure and Acute Coronary Syndromes

Asia-Pacific Cardiology 2007;1(1):22-3

Cardiac Resynchronisation Therapy in Heart Failure Patients with Atrial Fibrillation

European Cardiology 2010;6(2):92–5

NT-proBNP — A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure

US Cardiology 2004;1(1):1–5

Prognostic Significance of NTproBNP in Patients with a Clinical Diagnosis of Heart Failure and Preserved Left Ventricular Systolic Function

European Cardiovascular Disease 2007;3(1):41–2

Natriuretic Peptides - A Review

European Cardiology 2005;1(1):66-9

New Developments in the Management of Chronic Heart Failure

US Cardiology 2006;2(1):1-5

Novel Applications of Cardiac Biomarkers in Heart Failure

US Cardiology 2009;6(1):41–5

Heart Rate Variability and Chronic Heart Failure, From Bench to Bedside

Issues in Cardiac Resynchronization Treatment

US Cardiology 2007;4(1):85–7

The Use of B-type Natriuretic Peptide in Clinical Practice

European Cardiovascular Disease 2006;2(1):1–4

The Role of Beta Blockade in Heart Failure

European Cardiology 2005;1(1):1-6

The Treatment and Diagnosis of Decompensated Heart Failure

European Cardiovascular Disease 2006;2(1):105

Treatment of Acute Heart Failure - What We Have Learned to Date and How to Put it Into Practice

European Cardiovascular Disease 2006;2(1):100–2

Treatment of Decompensated Heart Failure

Echocardiography in Heart Failure—Current Applications

US Cardiology 2006;3(1):52–6

Echocardiography in the Detection and Monitoring of Heart Failure

European Cardiovascular Disease 2006;2(1):1–6

Echocardiographic Measurement of Mechanical Dyssynchrony in Heart Failure and Cardiac Resynchronization Therapy

Beyond the Apnea-Hypopnea Index—Prognostic Value of Other Elements of Polysomnography to Describe Sleep-disordered Breathing in Heart Failure

US Cardiology 2009;6(2):68–71

Emerging Cardiac Resynchronisation Therapy Indications

Eurpoean Cardiology 2011;7(1):29–33

Dynamic Bi-level Positive Airway Pressure Ventilation for the Treatment of Central Sleep Apnoea in Patients with Chronic Heart Failure

European Cardiovascular Disease 2006;2(1):106

Diastolic Heart Failure - Are Treatment Options Available?

US Cardiology 2006;3(2):125–7

The Limitations of Symptom-based Heart Failure Management

Cardiac Failure Review 2019;5(2):74–7.

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction

Cardiac Failure Review 2019;5(2):70–3.

Spending and quality after three years of Medicare's bundled payments for medical conditions: quasi-experimental difference-in-differences study

Rolnick JA, Liao JM, Emanuel EJ, et al. BMJ 2020;369:m1780.

Post-discharge acute care and outcomes following readmission reduction initiatives: national retrospective cohort study of Medicare beneficiaries in the United States

Khera R, Wang Y, Bernheim SM, et al. BMJ 2020;368:l6831.

Errors in analysis of heart failure hospitalizations with intravenous iron

Turgeon RD, Kolber MR. Am J Med 2020;133:E167–E168.

Measuring and improving the quality of heart failure care globally

Smith SC Jr, Fonarow GC, Zhao D. JAMA Netw Open 2020;3:e1918642.

Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis

Mahajan R, Stokes M, Elliott A, et al. Heart 2020;106:58–68.

Quality of care for patients hospitalized for heart failure in China

Gupta A, Yu Y, Tan Q, et al. JAMA Netw Open 2020;3:e1918619.

Adoption of sacubitril-valsartan in the Medicare population

Kahn PA, Riello III RJ, Ahmad T, Desai NR. Am Heart J 2020;223:81–3.

Evaluating risk prediction models for adults with heart failure: a systematic literature review

Di Tanna GL, Wirtz H, Burrows KL, Globe G. PLoS One 2020;15:e0224135.

Meta-analysis comparing torsemide versus furosemide in patients with heart failure

Abraham B, Megaly M, Sous M, et al. Am J Cardiol 2020;125:92–9.

Effect of uric acid-lowering agents on cardiovascular outcome in patients with heart failure: a systematic review and meta-analysis of clinical studies

Kanbay M, Afsar B, Siriopol D, et al. Angiology 2020;71:315–23.

Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

Arnott C, Li Q, Kang A, et al. J Am Heart Assoc. 2020;9:e014908.

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

Vos T, Flaxman AD, Naghavi M, et al. Lancet 2012;380:2163–96.

Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials

Ghosh-Swaby OR, Goodman SG, Leiter LA, et al. Lancet Diabetes Endocrinol 2020;8:418–35.

1.Heart disease and stroke statistics-2020 update: a report from the American Heart Association
Virani SS, Alonso A, Benjamin EJ, et al. Circulation 2020;141:e139-e596.
https://doi.org/10.1161/CIR.0000000000000757

2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211-59.
https://doi.org/10.1016/S0140-6736(17)32154-2